Imagine a world where a preventable disease still claims nearly 100,000 lives each year, mostly children. That's the grim reality of typhoid, a persistent threat in regions like sub-Saharan Africa and Asia, where clean water and sanitation remain out of reach for millions. But here's the glimmer of hope: a new weapon in our arsenal against this ancient foe—the typhoid conjugate vaccine (TCV).
The Global Burden of Disease study paints a stark picture: over 7 million typhoid cases annually, with children under 15 bearing the brunt. Thankfully, typhoid is preventable through vaccination. Currently, four TCVs are available globally, with two supported by Gavi, the Vaccine Alliance, for endemic countries. These vaccines are not only safe but highly effective, making them a cornerstone of typhoid control strategies. Expanding the TCV portfolio isn't just about adding options; it's about ensuring a stable supply chain and making these life-saving vaccines accessible to those who need them most.
And this is where the excitement begins: a new TCV, EuTYPH-C Inj.® Multi-dose, developed by EuBiologics, has shown remarkable promise in a Phase 3 study led by PATH. This study, conducted in Kenya and Senegal, compared EuTYPH-C Inj. Multi-dose to an established WHO-prequalified TCV, Typbar. The results, published in The Lancet Global Health, are truly encouraging. EuTYPH-C Inj. Multi-dose proved safe and highly immunogenic in typhoid-endemic populations, with no serious side effects reported.
Here's the really impressive part: at 28 days post-vaccination, nearly 100% of recipients showed a strong immune response, comparable to Typbar. This protection remained high even six months later. Patricia Njuguna, Senior Medical Officer at PATH, highlights the significance: “These results demonstrate the potential of EuTYPH-C Inj. Multi-dose to be a game-changer in preventing typhoid in vulnerable communities.”
The study went a step further, investigating the vaccine's compatibility with other routine childhood immunizations like measles-rubella and yellow fever. The good news? Co-administration didn't compromise the immune response to any of the vaccines, simplifying vaccination schedules and ensuring comprehensive protection for children.
These findings are crucial for EuTYPH-C Inj. Multi-dose's WHO prequalification, a stamp of approval that opens doors to procurement by UN agencies and Gavi. But here's where it gets controversial: while more TCV options are undoubtedly beneficial, ensuring equitable access and affordability remains a challenge. How can we guarantee that these life-saving vaccines reach the most vulnerable populations, regardless of their economic status?
A diversified TCV market fosters innovation, drives down costs, and reduces the risk of supply shortages. Dr. Emmanuel Mugisha, Global Director for Vaccine Implementation at PATH, emphasizes the progress: “Seven Gavi-eligible countries have already introduced TCVs, with more on the way.” The addition of EuTYPH-C Inj. Multi-dose would further strengthen this momentum, providing countries with more choices and a more stable supply.
EuBiologics has submitted its Phase 3 data to WHO for prequalification. If successful, EuTYPH-C Inj. Multi-dose could significantly increase the global TCV supply, ultimately saving more lives and protecting children from this preventable disease.
The fight against typhoid is far from over, but with advancements like EuTYPH-C Inj. Multi-dose, we're taking a giant leap forward. What do you think? Is enough being done to ensure global access to these life-saving vaccines? Share your thoughts in the comments below.
